---
layout: default
title: Aluminum Iodide
parent: 僅模型預測 (L5)
nav_order: 263
evidence_level: L5
indication_count: 0
---

# Aluminum Iodide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Aluminum Iodide: Insufficient Evidence for Drug Repurposing Evaluation

## One-Sentence Summary

Aluminum Iodide is a chemical compound with no established clinical indication on record in the US market.
The TxGNN model returned **no predicted new indications** for this compound at this time,
and **no clinical trials or publications** supporting any repurposing direction were identified.
A full evaluation cannot proceed until foundational data gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not established |
| Predicted New Indication | None (no TxGNN predictions returned) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only, no actual studies (pending prediction output) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Aluminum Iodide. No DrugBank ID was resolved, and the original indication field is empty, indicating this compound has no documented therapeutic use in the regulatory record. As a result, no mechanistic link to any disease can be established at this stage.

Additionally, the TxGNN prediction pipeline returned an empty `predicted_indications` list. This may indicate that the compound was not successfully mapped to a node in the knowledge graph, or that no disease associations exceeded the model's confidence threshold. Without a prediction target, the core premise of drug repurposing evaluation is absent.

Until MOA data is retrieved from DrugBank, the TFDA/FDA package insert warnings are reviewed, and a valid TxGNN prediction is generated, this report cannot advance beyond a data-gap acknowledgment.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

Aluminum Iodide holds no US FDA authorizations. The compound is not currently marketed.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
There are no TxGNN-predicted indications, no original clinical indication, no MOA data, and no US market authorization for Aluminum Iodide. The evidence base is entirely absent, making any repurposing evaluation premature.

**To proceed, the following is needed:**

- **[Blocking — DG001]** Retrieve the US FDA package insert or equivalent label to extract warnings and contraindications, enabling the S1 safety screen
- **[High — DG002]** Query the DrugBank API to obtain the mechanism of action, pharmacodynamic class, and DrugBank ID for Aluminum Iodide
- Re-run the TxGNN prediction pipeline after confirming the compound is correctly mapped to a knowledge graph node (verify INN spelling and DrugBank vocabulary match)
- If no DrugBank entry exists, evaluate whether this compound is a pharmaceutical ingredient or an industrial/research chemical — if the latter, it may be out of scope for drug repurposing
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

